Christopher Mason
Professor
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (36)
Detecting low variant allele fraction (VAF) mosaic variants without matching controls remains a major challenge in genomics, limited by technical noise, lack of benchmarks, and computational scalability. We present the DRAGEN mosaic caller, a hardware-accelerated approach identifying variants down to ∼1-2% VAF with low false-positive rates and hour-scale runtimes for mosaic SNV/indel detection from bulk sequencing. To support evaluation, we introduce a genome-wide low-VAF benchmark for variants between 1-10% VAF. Application to blood, sperm, and brain tissues revealed patterns, including mosaic hotspots and mutational signatures. The first analysis of HG002 blood showed that many “mosaic” variants defined from HG002 cell lines are likely culture-derived and not in vivo mutations. Importantly, DRAGEN also enables personalized assembly pangenome references to improve alignment and mosaic variant detection in complex regions. Together, this development makes routine low-VAF discovery feasible, opening new opportunities to study mosaic mutations in healthy and disease individuals.
Year:
2026
Disparities in formal bioinformatics training exacerbate the global skills gap, impeding the democratized application of advanced genomic technologies. To bridge this divide, we introduce a scalable, hybrid training framework designed to rapidly accelerate regional bioinformatics capacity. We exemplify this approach through the Eastern European Bioinformatics and Genomics (EEBG) workshop series — a cross-disciplinary initiative that pairs international faculty with local institutions to deliver modular, hands-on curricula. Functioning as a structured knowledge-transfer pipeline, the series has catalyzed a sustainable educational ecosystem, evidenced by the establishment of multiple independent summer schools across the region. The assessment of the 2025 EEBG workshop in Kraków, Poland, validates the model’s viability; participant metrics confirm high efficacy in skill acquisition (mean satisfaction: 4.4/5.0) and community building. Crucially, the hybrid delivery mode dismantled geographic barriers, serving as a vital mechanism for maintaining scientific continuity for researchers facing displacement and crisis. Synthesizing these outcomes, we define the core features of a replicable blueprint for scientific readiness in resource-constrained environments. We conclude by presenting a strategic roadmap — organized around infrastructure standardization, governance sustainability, and geographical expansion — for adapting this regional proof-of-concept into a global export-ready model, offering a critical path toward ensuring universal access to genomic innovation.
Year:
2026
Ferritin, consisting of ferritin heavy chain (FTH1) and light chain (FTL) subunits, is an essential intracellular iron storage protein fundamental for cellular function. However, the source and the biological role of extracellular ferritin (ex-ferritin) are less understood. Recent studies have linked elevated serum ex-ferritin with adverse outcomes in individuals with acute respiratory distress syndrome (ARDS). In this study, we demonstrate that both FTH1 and FTL are significantly enriched in the serum, blood monocytes, and alveolar macrophages (AMs) of individuals with ARDS, a phenomenon we successfully replicate in a murine hyperoxia-induced acute lung injury (HALI) model. We show that FTH1 is consistently upregulated in macrophages during lung injury development, and mice with a targeted deletion of FTH1 in myeloid (LysMcre) or resident lung macrophage (Cd11ccre) populations exhibit attenuated HALI. This reduced injury is linked to macrophage resistance to ferroptotic cell death, ferritinophagy, altered airway inflammatory responses, and lower lung extracellular iron and higher levels of FTL-ex-ferritin. Transplantation of FTL-ex-ferritin-enriched bronchoalveolar lavage fluid to wild-type mice protected against HALI. The ratio of FTL-ex-ferritin to FTH1 in the serum of individuals with ARDS who died was higher than that of those that survived, suggesting that the balance between FTH1 and FTL may play a role in injury modulation. Our findings highlight macrophage ferritin as a key regulator of macrophage survival and the response of the lung to injury, presenting a potentially targetable pathway for ARDS treatment.
Year:
2026
Inconsistent cellular lysis is a major source of inaccuracy in microbial analysis; there is a need to develop objective and standardized evaluation of lysis efficiency across diverse methods. Using a mock microbial community as a ground truth, we built a bioinformatic and experimental toolkit for this purpose, comparing the performance of chemical, thermal, enzymatic, and various physical lysis protocols. We evaluated over 150 lysis conditions and observed the highest performance from mechanically- and materially-optimized bead-based approaches. To extend these findings to a practical setting, we demonstrated that the Firmicutes to Bacteroides ratio, a frequently used compositional metric in gut microbiome analysis is biased heavily by insufficient lysis, indicating the importance of benchmarking ongoing methodological development.
Year:
2026
After the COVID-19 pandemic, wastewater monitoring is increasingly used for infectious disease surveillance. Using the data from a controlled experimental hospital setting, this paper examines the association wastewater SARS-CoV-2 with COVID-19 hospital admission and mortality, and whether this association varies by patients’ characteristics. Weekly wastewater samples were collected from the University of Miami (UM) hospitals where COVID-19 patients were admitted from February 2020 to October 2022, and SARS-CoV-2 was quantified using qPCR. Data on hospital admissions and their mortality and demographic characteristics and comorbidities were acquired from the UM hospitals. Using factor analysis and hierarchical clustering, patients were stratified into four clusters. Frist, we examined cross-correlations between time-lagged COVID-19 hospital admission and mortality, and time-lagged SARS-CoV-2 to identify appropriate time-lags. Second, we modelled daily hospital COVID-19 cases and mortality with respect to time-lagged SARS-CoV-2, vaccine status and time-lagged COVID-19 hospital cases (as proxy of the risk factor for the transmission of the disease for each cluster separately and for all clusters together. 1,856 COVID-19 patients were admitted in the UM hospitals during the study period and 347 (18.7%) of them died. In cluster 4 that represented patients with preexisting chronic health conditions and intubation, the fatality rate was 59%. COVID-19 hospital admission showed strong (temporal) autocorrelation, suggesting that the preexisting cases can indicate the transmission rate of infection. Our analysis suggests that a 1% increase in SARS-CoV-2 was associated with a 0.28% increase in COVID-19 related hospital admission (β ∼ 0.275; 95 % CI = 0.18 to 0.37; p < 0.01). Both a week lagged auto-regressive COVID-19 cases and SARS-CoV-2 in wastewater together explained 89% of the total variation in hospital admission due to COVID-19. Among four clusters, the second cluster of minority communities showed the strongest association between time-lagged SARS-CoV-2 in wastewater and hospital admissions due to COVID-19 followed by cluster 1 of adult patients with low prevalence of preexisting health conditions. However, time-lagged wastewater SARS-CoV-2 did not show any significant association with COVID-19 hospital admission for patients with the pre-existing health conditions. A week lagged wastewater SARS-CoV-2 did not show any significant association with COVID-19 mortality. Our results indicate that the association between time-lagged wastewater SARS-CoV-2 and COVID-19 hospital admission varied by patients’ characteristics, suggesting variations in SARS-CoV-2 shedding by patients’ characteristics. These findings warrant to incorporate patient-specific demographic characteristics and comorbidities in modelling infectious diseases surveillance using wastewater monitoring of the infectious agents.
Year:
2025
Traditional epigenetic aging clocks are limited because they do not incorporate clinical information and functional tests, and rely on DNA samples and methylation profiling infrastructure which are not easily accessible. To address these limitations, we built a new framework, FusionAge, with which we trained 26 aging clocks using interpretable nonlinear models, including deep neural networks (DNNs). Our results show that multimodal clocks built with DNNs significantly outperform clocks derived from single modalities or traditional linear models. FusionAge-derived biological age is more strongly associated with incident disease and mortality compared to chronological age in UK Biobank individuals. We validated these findings in the National Health and Nutrition Examination Survey, confirming that cardiorespiratory fitness is a major, consistent driver of biological age. Finally, we applied FusionAge to demonstrate its utility in detecting biological age changes in astronauts following spaceflight. Together, we demonstrate a powerful, portable framework for assessing biological age that captures the complex, multifactorial nature of human aging.
Year:
2025
Purpose: Mantle cell lymphoma (MCL) remains incurable despite therapeutic advances, highlighting the need for improved preclinical models. Existing transgenic MCL mouse models have significant limitations, restricting their translational value. Experimental Design: We generated an immunocompetent MCL model by overexpressing the key oncogenic drivers SRY-box transcription factor 11 ( SOX11 ) and Cyclin D1 ( CCND1) under the Eµ enhancer in C57BL/6 mice, aiming to replicate human MCL’s biological and pathologic features. Results: Eµ-SOX11CCND1 mice developed lymphoma marked by clonal B1a cell expansion in lymphatic and extranodal tissues. Morphologic, immunophenotypic, and transcriptional profiling revealed strong similarity to human MCL, with pathway analysis confirming significant molecular overlap. Importantly, lymphoma cells could be adoptively transferred into wild-type recipients, enabling therapeutic testing within an intact immune system. Conclusions: The Eµ-SOX11CCND1 mouse represents a robust and biologically relevant model that faithfully recapitulates human MCL. Its immunocompetent nature and adoptive transfer capability make it a valuable model for studying disease mechanisms and evaluating novel therapeutic approaches for patients with MCL.
Year:
2025
Myelodysplastic neoplasms (MDS) are genetically heterogeneous hematopoietic malignancies characterized by ineffective hematopoiesis, peripheral cytopenias, and risk of progression to acute myeloid leukemia. Diagnosis relies on subjective histomorphologic evaluation of bone marrow biopsies, leaving the significance of subtle microarchitectural changes unclear. We applied an AI-driven, whole-slide imaging–based multiplex immunofluorescence single-cell spatial phenotyping approach to diagnostic MDS samples (n=36), serial biopsies (n=29), precursor-state samples (n=13), and normal controls (n=21), profiling over 5 million cells. Compared with age-matched controls, MDS exhibited altered progenitor cell frequencies, abnormal erythroid and megakaryocyte morphology, disrupted erythroid islands, vascular displacement of hematopoietic stem and progenitor cells, and aberrant progenitor cell clustering. Several features correlated more strongly with specific mutations (e.g., SF3B1 , TP53 ) than with IPSS-M risk scores. We integrated these features into a composite MDS Microarchitectural Perturbation Score (MDS-MAPS) that aligned with clinical and genetic parameters across serial samples, revealing previously unrecognized, genotype-associated microarchitectural alterations in MDS. SIGNIFICANCE AI-driven spatial mapping detects previously unrecognized microarchitectural perturbations in MDS patient bone marrow biopsy tissues. Microarchitectural perturbations track closely with clinical and genetic parameters during the course of disease-modifying therapy. The detection of these features holds the potential to additionally inform clinical evaluation alongside standard clinical parameters.
Year:
2025
The transmission of the paternal genome requires extensive chromatin reorganization, in which nucleosomes are largely replaced by protamines that drive extreme condensation of the genome in the sperm head. Using Fiber-seq, we resolve patterns of paternal chromatin repackaging in sperm at single-molecule resolution, revealing the interplay between protamination and nucleosome retention. We find that nucleosome retention is probabilistic, with no locus universally occupied. Although promoters of spermatogenic genes preferentially harbor retained nucleosomes, the predominant carrier of paternal epigenetic information is protamine lacunae, accessible discontinuities in the protamine coat that preferentially mark critical regulatory elements. By contrast, centromere kinetochore binding regions robustly retain CENP-A mono-nucleosomes, providing a mechanism for the focal transmission of paternal centromeres. Finally, we find that paternal chromatin repackaging is altered in low-motility sperm. Together, these findings reveal distinct modes of paternal chromatin epigenetic inheritance with broad implications for development and infertility.
Year:
2025
Gliomas are a type of CNS tumors. Protein arginine methyltransferases (PRMTs) play important epigenetic regulatory roles in various cancers, including gliomas, by regulating DNA repair and cellular signaling pathways. Recent studies have also identified overexpression of PRMTs in gliomas and have shown that it is associated with tumor progression and resistance to conventional therapies. Targeting PRMTs has shown promising preclinical results demonstrating the potential to disrupt tumor growth, enhance DNA damage responses, and improve the sensitivity of gliomas to radiotherapy and temozolomide. In this review, we focus on the translational and clinical relevance of PRMT inhibitors in glioma subtypes, highlighting their latest clinical developments and ongoing clinical trials. Unlike previous reviews, our article provides an updated synthesis of clinical data, discusses challenges and opportunities in clinical translation, and suggests future directions for integrating PRMT inhibitors into glioma therapy.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Collaborators (102)
Mayumi Sugita
Weill Cornell Medicine
Cem Meydan
Assistant Professor
Weill Cornell Medicine
Karla Ballman
Chair / Consultant / Professor of Biostatistics
Mayo Clinic College of Medicine and Science
Andrew Stergachis
University of Washington
george church
Professor
Harvard Medical School
David Furman
Professor and Director AI & Bioinformatics Core; Head of Stanford 1,000 Immunomes Project
Buck Institute for Research on Aging
Olivier Elemento
Professor
Weill Cornell Medical College
Elinor Karlsson
Associate Professor
University of Massachusetts Chan Medical School
Walter Hanel
Ohio State University
Sylvain Costes
Professor
University of Pittsburgh
Jonathan Schisler
Assistant Professor
University of North Carolina at Chapel Hill School of Medicine
Robert Baiocchi
-
Serghei Mangul
University of Southern California
David W. Scott
The University of British Columbia
Andrea Guarracino
Assistant Professor
Translational Genomics Research Institute
Sonja Scholz
National Institute of Neurological Disorders and Stroke
JangKeun Kim
Senior Research Associate
Weill Cornell Medicine
Fritz Sedlazeck
Associate Professor
Baylor College of Medicine
Masafumi Muratani
Professor
University of Tsukuba
Rosa Lapalombella
Ohio State University
Gero Knittel
University Hospital Essen
Helena Solo-Gabriele
Professor
University of Miami
Heer Mehta
Assistant Professor
Baylor College of Medicine
Julie A. Meachen
Professor
Des Moines University
Dmitriy Zamarin
Professor and Section Head, Gynecologic Medical Oncology
Icahn School of Medicine at Mount Sinai
Wendy Béguelin
Assistant Professor
NYU School of Medicine
Erik Garrison
Associate Professor
University of Tennessee Health Science Center
Dylan McNally
Cornell University
Francisco J. Enguita
Director
Universidade de Aveiro
Justin Zook
National Institute of Standards and Technology
W. Scott Watkins
University of Utah
Massimo Loda
Chair
Weill Cornell Medical College
Steven Lipkin
Associate Professor
Weill Cornell Medical College
Jean Calleja Agius
Head of Department, Associate Professor
University of Malta
Bluma J Lesch
Associate Professor
Yale University
Minkyung Song
Assistant Professor
Sungkyunkwan University
Love Dalén
Professor
Stockholm University
Monica L. Guzman
-
Suzanne Cloonan
Associate Professor in Respiratory Biochemistry
Weill Cornell Medicine
Naresh Kumar
Teaching and Research, Associate Professor
University of Miami
Edward Schenck
Assistant Professor of Medicine
Cornell University
Martin Hölzer
Robert Koch Institute
Lapo Alinari
Ohio State University
Evan Eichler
Howard Hughes Medical Institute
Jiwoon Park
Weill Cornell Medicine
Satishkumar Singh
Ohio State University
Oona Shigeno Risse-Adams
Cornell University
Oleksyk Taras
Assistant Professor
Oakland University
Amal Thomas
University of Southern California
Juan Cubillos-Ruiz
Professor of Microbiology and Immunology
Weill Cornell Medicine
Samir Parekh
Director, Center of Excellence for Multiple Myeloma
Icahn School of Medicine at Mount Sinai
Robert Schwartz
Associate Professor
Weill Cornell Medicine
Luciano Martelotto
A/Professor, Head of the Development Laboratory
Harvard University
Brandi Cantarel
University of Texas Southwestern Medical Center
Wing Keung Chan
Assistant Professor
Ohio State University
Lawrence Grossman
Professor and Director
Wayne State University School of Medicine
Greger Larson
University of Oxford
Joanna Polanska
Professor of Bioinformatics, Head of the Department
Silesian University of Technology
Diana K. Morales
Associate Professor of Microbiology
Weill Cornell Medical College
Carlos Flores
Universidad de la Laguna
Glennis Logsdon
Assistant Professor
University of Pennsylvania
Deepika Awasthi
Weill Cornell Medicine
Robert Faryabi
Associate Professor
University of Pennsylvania
Marcus Gilbert
Københavns Universitet
Melissa Frey
Associate Professor
Weill Cornell Medicine
Afshin Beheshti
Professor
University of Pittsburgh
Nathanael Olson
National Institute of Standards and Technology
Anna Vähärautio
University of Helsinki
Matias Marin Falco
University of Helsinki
David Porubsky
-
John McDonald
Assistant Professor (Adjunct Track)
Georgetown University
Rachel J. O’Neill
University of Connecticut
Nathaniel Szewczyk
Professor
Ohio State University
Wanqiu Chen
Research Assistant Professor
Loma Linda University
Sara Zwart
University of Texas Medical Branch
Evelyn Cantillo
Weill Cornell Medicine
Alexander Zelikovsky
Distinguished University Professor
University of Georgia
christos proukakis
Professor of Neurology and Neurogenetics
University College London
Lorenzo Galluzzi
-
Jennifer McDaniel
National Institute of Standards and Technology
qiang pan-hammarstrom
Professor, head of the Immunology Division
Karolinska University Hospital
Evanthia Roussos Torres
Assistant Professor
University of Southern California Norris Comprehensive Cancer Center
Paweł Łabaj
dr hab. inż., prof. UJ
Jagiellonian University
Joshua Fein
Assistant prof
Weill Cornell Medicine
Harriet Dashnow
Assistant Professor
University of Colorado Anschutz Medical Campus
Yan Guo
University of Miami
Karl Koehler
Assistant Professor
Harvard Medical School
Lalit Sehgal
Associate Professor
Ohio State University
Chaz Hyseni
Uppsala University
Charles Wang
Professor/Director
Loma Linda University
Hui-Hsuan Kuo
Northwestern University
Jasmine Plummer
Director, Associate Member
St. Jude Children's Research Hospital
Remi Klotz
Assistant Professor of Research
University of Maryland
Violetta Leshchenko
Senior Scientist
Icahn School of Medicine at Mount Sinai
Charles Lee
Director and Professor
The Jackson Laboratory for Genomic Medicine
Min Yu
Professor
-
Hans Christian Reinhardt
-
Sebastian E. Carrasco
Weill Cornell Medicine
Bridgett M. Vonholdt
Associate Professor
Princeton University
Bérénice Benayoun
Assistant Professor
University of Southern California
Ari M. Melnick
Director
Josep Carreras Leukaemia Research Institute
Paul C Boutros
University of California
Make your next move.
Prepare your application
Review drafts before you send them.